Verastem Oncology, a Koch Institute spinout, has earned FDA approval for a combination of avutometinib and defactinibto treat recurrent low-grade serous ovarian cancer. The oral therapy targets key resistance pathways, offering a long-awaited option for patients with this hard-to-treat cancer.